3 citations
,
August 2013 in “Journal of the National Cancer Institute”
This study reported an almost doubling of advanced breast cancer incidence in women under 40 over three decades, but its significance remains uncertain and requires further confirmation.
This study found that administering chemotherapy to premenopausal women with Stage II breast cancer significantly improved disease-free intervals and increased survival, while postmenopausal women receiving sufficient doses also saw prolonged disease-free periods.
This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.
March 2021 in “Revista Colombiana de Cancerología”
This report details the first two cancer patients with COVID-19 and co-infection cases at the Instituto Nacional de Cancerología, ESE, and presents their clinical symptoms and complications.
Federal funding for medical research in the U.S. has been halted, potentially delaying new treatments. Hair loss treatments like finasteride and minoxidil are unlikely to be impacted as they are typically funded by private companies.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.
Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.